.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Blood-Based Proteomic Test for NSCLC Will Be Reimbursed by UnitedHealthcare

Published on: May 12, 2015

The diagnostic test, developed by Biodesix, Inc, will help guide treatment decisions in patients with advanced lung cancer.

Biodesix, Inc, today announced that its VeriStrat test received a positive coverage decision from UnitedHealthcare, one of the largest commercial insurance companies in the US, with a published 44.7 million covered lives. In its Medical Policy, UnitedHealthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung cancer (NSCLC).”

VeriStrat, included in the standard of care guidelines, is a blood-based proteomic test that provides physicians with prognostic and predictive information that helps guide treatment of advanced NSCLC. Patients with a VeriStrat Poor test result have a shorter median overall survival than those with a VeriStrat Good result. Understanding the patient’s disease state can help inform physicians’ decisions on chemotherapy, palliative care or clinical trials.

Read the complete news release on Yahoo!: http://yhoo.it/1HcbqFK